Tuesday, February 20, 2018

Indonesia Hospital Market Future Outlook to 2022: Ken Research

The report titled “Indonesia Hospital Market Outlook to 2022 - By Public & Private Hospital, By General & Specialty Hospital, By Region” provides information on market size for Indonesia Healthcare and hospital. The report covers hospital market segment by public & private hospitals, by general & specialty hospitals and by region along with competitive landscape of major hospitals including Mitra Keluarga Karyasehat Tbk Pt, Siloam Hospitals, PT Sejahteraraya Anugrahjaya, Sarana Meditama, Rumah Sakit Pondok Indah, Surya Husadha General Hospital, Jakarta Eye Center, Rumah Sakit Dr Oen Surakarta, Pertamedika (Rumah Sakit Pusat Pertamina), Kaish Ibu Hospital, Hermina Hospital Group, Awal Bros Hospital Group and Sari Asih. The report concludes with market projections for future and analyst recommendations highlighting the major opportunities and cautions.
Indonesia Hospital Market Overview
The hospital market in Indonesia forms an important component of the overall healthcare market in Indonesia. Indonesia Hospital Market grew from USD ~ million in the year 2012 to USD ~ million in the year 2017. The number of public hospitals increased from ~ in 2012 to ~ in 2016 and the private hospitals increased from ~ in 2012 to ~ in 2016. The market has been facilitated by increasing prevalence of the severe chronic diseases in Indonesia. Several diseases such as Pneumonia, Multi-bacillary (MB) Leprosy and Diarrhea had increased in the year 2015. The coverage of pneumonia findings in under-fives increased to ~% in 2015 against ~% in the 2014, the proportion of people under MB Leprosy increased to ~% in 2015 against ~% in 2014. Further, the private firms have increased focus on high revenue intensity streams which includes secondary care, tertiary care and quaternary care and comprehensive health screening programs to increase contribution from outpatients.
Indonesia Hospital Market Segmentation
By Public and Private Hospitals: Public hospitals have accounted for ~% of the number of hospitals on account of the increase in the government budget allocation on healthcare. Private hospitals have registered ~% of the total hospitals in Indonesia in 2016 as the demand for modern medicine and specialist services increased in the country.
By General and Specialty Hospitals: General hospitals have accounted for ~% of the total number of hospitals whereas specialty hospitals which include hospitals such as mental hospital, leprosy hospital, eye hospital and others have registered ~% of the total number of hospitals.
By Type of Specialty Hospitals: Mother and children has accounted for ~% of the number of specialty hospitals in 2015 followed by maternity hospitals with ~% and mental hospital with ~% of the share in 2015. Rest of the market includes Eye hospital, leprosy hospital and pulmonary tuberculosis hospital with ~%, ~% and ~% respectively of the total number of specialty hospitals in 2015. Other specialized hospitals have registered ~% of the market share in 2015.
By Region: East Java has gathered ~% of the number of beds in Indonesia in 2016 owning to the high number of disaster in the region followed by Central Java with ~%, West Java with ~%, Jakarta with ~%, North Sumatra with ~%, South Sulawesi with ~%. On the other hand, underdeveloped regions such as North Kalimantan, West Sulawesi and North Maluku have accounted for ~%, ~% and ~% of the number of hospital beds in 2016 respectively.
Indonesia Hospital Market Competition Overview
There are ~ hospitals in Indonesia in 2016 of which ~% are public hospitals and ~% are private hospitals. There are ~ major private hospitals in Indonesia operated by top 10 private participants in 2015. Long waiting queues at public hospitals, quality of service and need for specialist doctors will drive Out-of-pocket patients to these private hospitals by 2019. Major hospitals include Siloam Hospital group, Hermina Hospital Group, Rumah Sakit Mitra, Awal Bros Hospital Group, Sari Asih Group, Ramsay Sime Darby Healthcare and Eka Hospital group. Major competition parameters for private hospitals are facilities, number of beds, number of hospitals, fees, quality of doctors/medical practitioners and specialization.
Indonesia Hospital Market Future Potential
The hospitals market in Indonesia is expected to grow at a five year CAGR of ~% during 2017-2022. The hospital market is expected to rise owing to the government support in the industry which will encourage foreign investment in the sector. More than 35,000 new beds are likely to be added in Indonesia by 2020. Moreover, due to the entry of new participants into the private hospital market and expansion of existing ones, the country is expected to achieve ~ beds per 1,000 people by 2019. The number of hospitals is expected to increase to ~ in 2022 in which ~ are expected to be private and ~ are expected to be public.
Key Topics Covered in the Report:
Hospitals in Jakarta Area
Jakarta Hospital Market
Indonesia Hospital Revenue
Inpatient Revenue Indonesia
Outpatient Revenue Indonesia
Number of Inpatients Indonesia
Number Outpatients Indonesia
Indonesia Private Hospital Market
Hospitals and Clinics Market Indonesia
Hospital Market Indonesia
Siloam Hospital Competitor Indonesia
Hospital Market Trends Indonesia
Number of Public Hospitals Indonesia
Number of Private Hospitals Indonesia
Trends Indonesia Hospital Industry
Challenges Indonesia Hospital Market
Major Hospital Projects in Indonesia
Regulations Indonesia Hospital market
Indonesia Number of General Hospitals
Number of Specialty Hospitals Indonesia
Type of Specialty Hospitals Indonesia
Major Companies Hospitals Market Indonesia
Business Model Indonesia Hospital
Hospital Spending Indonesia
Revenue Streams Hospitals Indonesia
Investment in Hospital Indonesia
Super Specialty Hospital Market Indonesia
General Hospital Valuation Indonesia
Acquisitions Hospital Indonesia
Funding Hospital Indonesia
For more information on the research report, refer to below link:
Related Reports by Ken Research
Contact:         
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Monday, February 19, 2018

Indonesia Pharmaceutical Market is expected to Reach USD 10.3 Billion by 2022: Ken Research

Indonesia pharmaceutical market segment (by therapeutic segment, by domestic & international players, by generic & patented drug, by OTC & prescription drugs, by domestic sales & exports and by region), competitive landscape of major players in the Indonesia pharmaceutical market covering company profile of PT Kalbe Farma, PT Sanbe Farma, PT SOHO Global Health, PT Dexa Medica, PT Pharos, PT Kimia Farma, PT Tempo Scan Pacific Tbk, PT Merck Tbk, Fahrenheit, Sanofi Aventis, PT. Novell Pharmaceutical Laboratories, Biofarma, Darya Varia and Konimex. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.
Majority pharmaceutical companies are located in West Java and Jakarta due to favorable tax incentives, well developed infrastructure and greater access to medicinal herbs.
Healthcare industry in Indonesia is driven by the surging number of hospitals, clinics and pharmacy stores coupled with rising prevalence of chronic diseases including diabetes, HIV, Tuberculosis and others. It is anticipated that over 35,000 new beds will be added in Indonesia by 2020. Indonesia is anticipated to achieve 1.5 beds per 1,000 people by 2019 with the entry of new private hospitals and increased capacity of existing ones.
Indonesia Pharmaceutical Market Research Report
The pharmaceutical sector will observe a rise in demand for nutrition and vitamin and dietary supplements. Pharmaceutical companies are anticipated to shift focus to other niche segments including combined dosages, novel drug delivery areas besides manufacturing generic and patented drugs. Indonesia pharmaceutical market is anticipated to grow in future with surging ageing population, increased health care spending and rise in lifestyle related diseases.
The distribution channel will be dominated by hospital and clinics which implies a shift from physicians and pharmacies. So the companies now need to target the hospitals and clinics more in their marketing activities. The industry will witness an increased investment from foreign players and the prevalence of chronic diseases such as cancer, HIV and others will lead to increase demand for innovative products particularly in the field of biopharmaceuticals. With the increase in role of government in the Indonesian healthcare industry, the pharmaceutical companies need to look for government tenders as government opts for e-procurement methods to procure medicines for various public and private hospitals participating in the universal healthcare system
Emerging Contract Development and Manufacturing Organizations market, increasing number of mergers & acquisitions coupled with elevating prevalence of chronic and lifestyle diseases will propel the Indonesia pharmaceutical market revenue in future.
Ken Research in its latest study, “Indonesia Pharmaceutical Market Outlook to 2022 – By Therapeutic Segment (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology), By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region”, suggests that demand for pharmaceutical products in the market will continue to grow in Indonesia owing to favorable government regulations for FDI inflows and growing vitamin and dietary supplements market.
Key Topics Covered in the Report:
Pharmaceutical Market Size Indonesia
Kalbe Farma Competitors Indonesia
Healthcare Spending Indonesia
Obese Population Indonesia
Indonesia Healthcare Market Future
Animal Pharmaceutical Market Indonesia
Biopharmaceutical Market Indonesia
Indonesia Vaccine Market
Generic Drug Market Size Indonesia
Market Share of Major Players in Indonesia Pharmaceutical Market
Vitamin and Dietary Supplement Market Indonesia
Major Therapeutic Segment in Indonesia Pharmaceutical Market
Type of Generic Drugs in Indonesia
Mergers & Acquisitions in Indonesia Pharmaceutical Market
Pharmaceutical Market Exports Indonesia
Pharmaceutical Market Future Trends Indonesia
Number of Pharmaceutical Companies Indonesia
Trends Indonesia Pharmaceutical Market
Issues & Challenges in Indonesia Pharmaceutical Market
Government Regulations in Indonesia Pharmaceutical Market
Number of Healthcare Centers in Indonesia
Budget Allocation on Healthcare Indonesia
Major Companies Pharmaceutical Market Indonesia
For more information on the research report, refer to below link:
Related Reports by Ken Research
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Lung Transplant Rejection Global Clinical Trials Review H2 2017: Ken Research

GlobalData'sclinical trial report, Lung Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Lung Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using GlobalData'sproprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months

Key Topics Covered in the Report:
Lung Transplant Rejection Global Clinical Trials
Global Lung Transplant Rejection Clinical Trials Market Size
Global Lung Transplant Rejection Clinical Trials Market Trends
Global Lung Transplant Rejection Clinical Trials Market Outlook
Global Lung Transplant Rejection Clinical Trials Market Demand
Global Lung Transplant Rejection Clinical Trials Market Forecast
Global Lung Transplant Rejection Clinical Trials Market
Europe Lung Transplant Rejection Clinical Trials
Global Lung Transplant Rejection Clinical Trials Market
Global Lung Transplant Rejection Clinical Trials Market Value

To know more, click on the link below:

Contact:        
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Friday, February 16, 2018

Indonesia Pharmaceutical Market Outlook to 2022: Ken Research

Indonesia Pharmaceutical Market Outlook to 2022 - By Therapeutic Segment (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology), By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region" provides information on market size for Indonesia Healthcare and pharmaceutical.

The report covers aspects such as healthcare market segment (by hospitals, pharmaceuticals, medical devices and clinical laboratory), pharmaceutical market segment (by therapeutic segment, by domestic & international players, by generic & patented drug, by OTC & prescription drugs, by domestic sales & exports and by region), competitive landscape of major players in the Indonesia pharmaceutical market, and covering competitive landscape of major pharmaceutical companies including PT Kalbe Farma, PT Sanbe Farma, PT SOHO Global Health, PT Dexa Medica, PT Pharos, PT Kimia Farma, PT Tempo Scan Pacific Tbk, PT Merck Tbk, Fahrenheit, Sanofi Aventis, PT. Novell Pharmaceutical Laboratories, Biofarma, Darya Varia and Konimex. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.
Indonesia Pharmaceutical Market
Indonesia Pharmaceutical market has registered an increase in the revenue at a CAGR of ~% from USD ~ billion in 2012 to USD ~ billion in 2017.
By Therapeutic Segment: Anti-infective drug sale has contributed to the largest share of ~% in the revenue share of Indonesia Pharmaceutical industry in 2017. This is mainly due to high prevalence of bacterial and communicable diseases. This is followed by Gastrointestinal and metabolism drugs with ~%, cardiovascular system drugs with ~%, Central Nervous system drugs with ~%, Respiratory system drugs with ~%, Musculoskeletal system drugs with ~%, dermatology drugs with ~%, genitourinary and hormonal drugs with ~%, blood related drugs with ~%, oncology with ~% and rest of the therapeutic segments with ~% of the revenue share in 2017.
By Domestic and International Players: Domestic players have accounted for ~% of the revenue in Indonesia pharmaceutical market in 2017 driven by the implementation of JKN (National Health Insurance System) in 2014. International players have captured ~% of the revenue share in 2017 driven by favorable government norms for foreign ownership.
By Generic and Patented Drug: Generic drugs have accounted for the major revenue share of ~% in 2017 driven by the increased demand from government run hospitals and clinics. The share of patented drugs has increased from ~% in 2013 to ~% in 2017. Further, ethical generic drugs have accounted for ~% of the Indonesia generic drug market revenue in 2017 followed by free sale drugs with ~% and unbranded drug sale with ~%.
By OTC and Prescription Drugs: The Prescription drugs sales have accounted for ~% of the revenue share in Indonesia Pharmaceuticals Market. OTC drugs have accounted for ~% of the revenue share in 2017. This segment is driven by increased tendency of Indonesians to treat them and take self medication
By Domestic Sales and Exports: Domestic sales have accounted for a majority revenue share of ~% in 2017 whereas exports have accounted for a small share of ~%. The domestic market is dominated by the sale of low priced ethical generic medicines.
Indonesia Pharmaceutical Market Competition Overview
Indonesia Pharmaceutical market is dominated by domestic players which control ~% of the market in 2017. Recent favorable government regulations have facilitated the entry of foreign players in the space. There are 206 pharmaceutical companies (182 domestic and 24 international companies) located in Indonesia and ~% of them are located in Java in 2016. These players compete on the basis of distribution network, product portfolio, marketing activities and research and development. The domestic players dominate the generic drug and over the counter drug segment. International players have better expertise, skilled labor and infrastructure to produce such medicines at competitive prices. While domestic companies dominate the market for low cost generic drugs, multinational players have taken over high-demand, specialized segments and pharmaceuticals services ranging from capsule provision to instrumentation and packaging.
Indonesia Pharmaceutical Market Future Potential
Indonesia pharmaceutical industry is expected to increase from USD ~ billion in 2018 to USD ~ billion at a growth rate of ~%. The industry growth will be led by Indonesia’s large population and growing middle-income class, supportive government policies and higher investment in the industry. With the increase in incidence of communicable diseases such as HIV, TB, therapeutic segments such as anti infectives and respiratory are expected to grow. Major companies are expected to increase investment in nutritional and herbal medicines due to changing preference in the industry. Apart from manufacturing generic and patented drugs, pharmaceutical companies will shift focus to other niche segments such as combined dosages, novel drug delivery areas. Further in order to overcome the shortcomings, Contract Development and Manufacturing Organizations (CDMOs) will emerge as an attractive resource for manufacturers seeking to expand their capacities.
Key Topics Covered in the Report:
  • Indonesia Healthcare Market Size, 2012-2017
  • Indonesia Pharmaceutical Market Size, 2012-2017
  • Indonesia Pharmaceutical Market Segmentation (by therapeutic segment, by domestic & international players, by generic & patented drug, by OTC & prescription drugs, by domestic sales & exports and by region)
  • Trends and Developments in Indonesia Pharmaceutical Market
  • Issues and Challenges in Indonesia Pharmaceutical Market
  • Government Initiatives, Rules and Regulations in Indonesia Pharmaceutical Market
  • Indonesia Pharmaceutical Market Competitive Landscape
  • Indonesia Pharmaceutical Future Outlook and Projections, 2018-2022
  • Indonesia Healthcare Future Outlook and Projections, 2018-2022
  • Analyst Recommendations
  • Macro-economic Factors Impacting Indonesia Healthcare Market
Source: https://www.kenresearch.com/healthcare/pharmaceuticals/indonesia-pharmaceutical-market/143542-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249

Global Lung Infections Clinical Trials Market Research Report to 2017: Ken Research

GlobalData'sclinical trial report, Lung Infections Global Clinical Trials Review, H2, 2017" provides an overview of Lung Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using GlobalData'sproprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months

Key Topics Covered in the Report:
Global Lung Infections Clinical Trials Market Research Report
Global Lung Infections Clinical Trials Market Size
Global Lung Infections Clinical Trials Market Trends
Global Lung Infections Clinical Trials Market Forecast
Global Lung Infections Clinical Trials Market Outlook
Global Lung Infections Clinical Trials Market Share
Global Lung Infections Clinical Trials Market
Global Lung Infections Clinical Trials Industry Research
 Europe Lung Infections Clinical Trials Market Volume
US Lung Infections Clinical Trials Market Revenue

To know more, click on the link below:

Contact:        
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Indonesia Healthcare Market has been driven by Increase in Foreign Direct Investment and favourable Government Initiatives: Ken Research

Implementation of JKN (National Health Insurance System) by the government, growing foreign investment in the private hospital sector, expansion of service and product portfolio by major private hospital chains and pharmaceutical companies were the key factors driving growth in Indonesia Healthcare Market.
The Indonesia healthcare market has shown a positive incline during 2012-2017 but with respect to the expanding population of Indonesia, the market is still underserved especially in the underdeveloped and rural areas as of 2017.
The implementation of JKN scheme by the government has led to rise in demand for primary healthcare facilities and increased generic drug sale. This has further led to increase in number of outpatients and improvement in margins mainly from upgrades for standard JKN fees and services.
The industry has undergone various deregulation programs which has encouraged foreign investment in the industry. For instance, the government removed pharmaceutical industry from its negative investment list implying 100% foreign ownership is allowed. Further, foreign players are allowed to hold 67% stake in both general and specialty hospitals. Foreign investors such as Malaysia-based Creador injected USD 45 million in Medikaloka Hermina, the operator of the Hermina Hospital Group. Netherlands has accounted for the largest share of USD 10 million in the total foreign investment of USD 14.3 million during the first half of 2017.
The market has witnessed enhancing innovation in nutritional health segment and biopharmaceuticals due to growing prevalence of lifestyle diseases such as diabetes, hypertension and obesity. International companies have benefitted from rising demand in medication for chronic diseases such as Tuberculosis, HIV and others. Furthermore, increase in demand for generic medicines has led the major players in the industry to expand their production capabilities. In order to capture the market potential, the industry has observed various mergers and acquisitions over the last few years. Further, there are startups such as PesanLab which offers a booking service for laboratory testing, or Homecare24 which offers on-demand home care services. This will further lead to integration of healthcare services in the country.
The report titled “Indonesia Healthcare Market Outlook to 2022 - by Hospitals, Clinical Laboratories, Pharmaceutical, Pharmacy Chains, Medical Device Segment” by Ken Research suggested a growth at a CAGR of 9.6% in revenue in Indonesia Healthcare Market by 2022.
Key Topics Covered in the Report:
Medical Devices Market Indonesia
Indonesia Healthcare Statistics
Diabetes Prevalence Indonesia
Pharmaceutical Market Indonesia
Obese Population Indonesia
Number of Hospitals Indonesia
Healthcare Spending Indonesia
Number of Puskesmas Indonesia
Medical Device Imports Indonesia
Type of Medical Devices Indonesia
Tuberculosis Prevalence Indonesia
For more information on the research report, refer to below link:
Related Reports by Ken Research
Contact:         
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Thursday, February 15, 2018

Lumbar Hernia/Bleichner'shernia Global Clinical Trials Review H2 2017: Ken Research

GlobalData'sclinical trial report, Lumbar Hernia/Bleichner'sHernia Global Clinical Trials Review, H2, 2017" provides an overview of Lumbar Hernia/Bleichner'sHernia clinical trials scenario. This report provides top line data relating to the clinical trials on Lumbar Hernia/Bleichner'sHernia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using GlobalData'sproprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months

Key Topics Covered in the Report:
Lumbar Hernia/Bleichner'shernia Global Clinical Trials Review H2
Global Lumbar Hernia/Bleichner'shernia Clinical Trials Market
Global Lumbar Hernia/Bleichner'shernia Market Size
Global Lumbar Hernia/Bleichner'shernia Market Trends
Global Lumbar Hernia/Bleichner'shernia Clinical Trials Market Growth
Global Lumbar Hernia/Bleichner'shernia Clinical Trials Market Revenue
Global Lumbar Hernia/Bleichner'shernia Clinical Trials Market Outlook
Lumbar Hernia/Bleichner'shernia Global Clinical Trials Europe
Global Lumbar Hernia/Bleichner'shernia Industry Research
Global Lumbar Hernia/Bleichner'shernia Market Volume

To know more, click on the link below:

Contact:        
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204